Quaero Life Science

Executive Summary

Quaero Life Science is a private, clinical-stage Chinese biotechnology company developing novel small molecule therapies for cancer and autoimmune diseases. Founded in 2018 and headquartered in Shanghai, the company focuses on innovative biological pathways such as protein-protein interactions and epigenetic regulators. It has advanced several candidates into early and mid-stage clinical trials, targeting indications in oncology and immunology. While specific pipeline details are limited, the company's approach addresses high-unmet-need areas with potential for first-in-class therapies. As a private entity, Quaero Life Science operates with less public disclosure than public biotechs, but its stage and focus suggest it may be approaching key data readouts or seeking partnership opportunities. The company's progress in a competitive landscape underscores its potential, though execution risk and market dynamics remain considerations.

Upcoming Catalysts (preview)

• Q4 2026Phase 2 Data Readout for Lead Asset in Oncology40% success
• Q3 2026Financing Round or Strategic Partnership60% success
• Q1 2027IND Filing for New Epigenetic Regulator Program50% success